Results 11 to 20 of about 140,304 (256)
Interferon Lambda Delays the Emergence of Influenza Virus Resistance to Oseltamivir
Microorganisms, 2021 Influenza viruses are a leading cause of morbidity and mortality worldwide. These air-borne pathogens are able to cross the species barrier, leading to regular seasonal epidemics and sporadic pandemics.
Chiara Medaglia +6 more
doaj +1 more source
Antiviral drugs and antiviral drug resistance [PDF]
Current Opinion in Virology, 2011 Antiviral drugs and antiviral drug resistance can be matters of life and death for patients suffering from viral infections. They also can be valuable tools for understanding virus biology and biochemistry. Triumphs of antiviral therapy include acyclovir to treat genital herpes [1–4], triple combination chemotherapy for AIDS [5,6], and, quite recently,
Donald M, Coen, Richard J, Whitley
openaire +2 more sources
ARHAI: antiviral resistance [PDF]
Journal of Antimicrobial Chemotherapy, 2012 Development of antiviral resistance is a particular concern for the Advisory Committee on Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI). Over the last 4 years, considerable time has been devoted to examining the ability of the UK to monitor the presence and transmission of antiviral resistance. Resistances to antiviral agents in
C Y William, Tong +2 more
openaire +2 more sources
Pathogens, 2022 Baloxavir marboxil (BXM) is an antiviral drug that targets the endonuclease of the influenza polymerase acidic (PA) protein. Antiviral resistance, mainly mediated by the I38T PA substitution, readily occurs in both A(H1N1) and A(H3N2) viruses following a
Amel Saim-Mamoun +3 more
doaj +1 more source
Computational and Structural Biotechnology Journal, 2020 There are no approved target therapeutics against SARS-CoV-2 or other beta-CoVs. The beta-CoV Spike protein is a promising target considering the critical role in viral infection and pathogenesis and its surface exposed features. We performed a structure-
João Trigueiro-Louro +4 more
doaj +1 more source
BMJ, 1998 The development of effective antiviral drugs is an important biomedical scientific achievement of the late 20th century. Highly potent drugs are now available against herpes viruses, HIV, hepatitis B virus, and influenza virus. This list will extend to papillomaviruses, respiratory viruses, enteroviruses, and hepatitis C virus over the next 5-10 years.
D, Pillay, M, Zambon
openaire +4 more sources
Retrovirology, 2017 The first responders of human antiviral immunity are components of the intrinsic immune response that reside within each and every one of our cells.
Guoli Shi +2 more
doaj +1 more source
Frontiers in Microbiology, 2020 Hepatitis B virus (HBV) is a highly variable DNA virus due to its unique life cycle, which involves an error-prone reverse transcriptase. The high substitution rate drives the evolution of HBV by generating genetic variants upon which selection operates.
Natalia M. Araujo +2 more
doaj +1 more source
Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade [PDF]
Clinical and Molecular Hepatology, 2013 Although much advancement has been achieved in the treatment of chronic hepatitis B, antiviral resistance is still a challenging issue. Previous generation antiviral agents have already developed resistance in a number of patients, and it is still being ...
Hyung Joon Yim, Seong Gyu Hwang
doaj +1 more source
New Treatment Options for Refractory/Resistant CMV Infection
Transplant International, 2023 Despite advances in monitoring and treatment, cytomegalovirus (CMV) infections remain one of the most common complications after solid organ transplantation (SOT).
Carla Simone Walti +3 more
doaj +1 more source